Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Tesla Raises Cybertruck Prices by $5,000 in US 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Trump Buys SpaceX Shares After Record IPO 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Nvidia Options Price in $280 Billion Earnings Swing 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
 - EconoTimes)
Add as a preferred source on Google
MONTREAL, May 01, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.
At the time of approval of EGRIFTA® on November 10, 2010, the FDA requested that the company conduct two large safety clinical trials.
The FDA determined that these two large-scale post-approval clinical trials are no longer required as the current labeling adequately reflects the safety profile of EGRIFTA®. The FDA also concluded that the size of the HIV patient population with lipodystrophy did not make such a requirement feasible.
In its most recent audited financial statements, for the year ended November 30, 2017, Theratechnologies estimated that the post-approval commitments would require an additional investment of US$13 million, which will no longer be required.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236
